



## Arbutus to Participate at JMP Securities Life Sciences Conference

June 13, 2019

WARMINSTER, Pa., June 13, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael Sofia and Dr. Gaston Picchio will participate in a fireside chat at JMP Securities Life Sciences Conference at 10:00 am ET on Thursday, June 20, 2019.

A live webcast of the fireside chat can be accessed through the Investors section of Arbutus' website at [www.arbutusbio.com](http://www.arbutusbio.com). A replay of the webcast will be available for 90 days following the live presentations.

### About Arbutus

Arbutus Biopharma Corporation is a publicly-traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care and contribute to a curative combination regimen. For more information, visit [www.arbutusbio.com](http://www.arbutusbio.com).

### Contact Information

#### Investors

Mark Murray  
President and CEO  
Phone: 604-419-3200  
Email: [ir@arbutusbio.com](mailto:ir@arbutusbio.com)

Pam Murphy  
Investor Relations Consultant  
Phone: 604-419-3200  
Email: [ir@arbutusbio.com](mailto:ir@arbutusbio.com)



Source: Arbutus Biopharma Corporation